INGN — Stock Film
STOCK FILMSCENE 1/10INGN · $5.31
Stock Expert AI presents
INGN
Inogen, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Inogen, Inc. What it actually does.

Develops portable oxygen concentrators for patients with chronic respiratory conditions. Now — the numbers.

on the stock market since 2014
753 employees
$143.8M market value
Revenue last year:
$348.7M
The loss that same year:
$22.7M
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

In the vault right now:
$119.6M
DEBT: $17.5M
At this pace, that money lasts about 5.3 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
0.4×

This company is not turning a profit, so the market is pricing its sales instead: 0.4× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 82% of them.

Analysts' average target sits 390% above today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
74
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
22
very weak

Clearly below the class average.

VALUATION
82
very strong

The price looks reasonable next to what the company earns.

GROWTH
22
very weak

Clearly below the class average.

PRICE MOMENTUM
31
very weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Growth: Sales growth trails the sector average.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales are holding up

The company sells $348.7M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 41 buys and 36 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Running at a loss

A loss of $22.7M against $348.7M in annual sales.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 22/100.

3
THE RISKS · 3/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 22/100.

FINALE · THE GRADE
D
36 / 100 · MoonshotScore

On our five-subject report card, INGN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: INGN’s sales are going backwards, and it closed last year at a loss. The road back runs through both.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film